Clinical Trials Logo

Type1diabetes clinical trials

View clinical trials related to Type1diabetes.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT03703440 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 1

Group Education Trial to Improve Transition in Type 1 Diabetes

GET-IT-T1D
Start date: November 19, 2019
Phase: N/A
Study type: Interventional

The investigators will conduct a randomized controlled trial (RCT) to examine group education visits as an innovative and potentially cost-effective approach to transition care delivery, that can be easily integrated into usual diabetes care. Among emerging adults with type 1 diabetes (T1D), the investigators aim to assess the effect of group education visits integrated into pediatric care, compared with usual care on Hemoglobin A1c (HbA1c), adverse outcomes and psychosocial measures after the transfer to adult care. The investigators will conduct a multi-site, parallel group, blinded (outcome assessors, data analysts), superiority Randomized Controlled Trial (RCT) of adolescents with T1D (17 years of age) followed at one of the two university teaching hospital-based pediatric diabetes clinics in Montreal. Interventions will occur over 12-months. Follow-up will be to 24 months from enrollment.

NCT ID: NCT03215914 Active, not recruiting - Hypoglycemia Clinical Trials

Hybrid Closed Loop Insulin Delivery System in Hypoglycemia

Aim2
Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Can a type 1 diabetic adult avoid low glucoses and regain hypoglycemia awareness using a hybrid closed loop insulin delivery system? Involvement is 22 months (13 visits) and includes a 4-week Screening Phase and an 18-month Intervention Phase. Participants will undergo 3 Hyperinsulinemic Clamps done at: Baseline (before starting the device and after completing the screening), 6 months (after using the device 6 months), and after using the device for 18 months. This metabolic testing will allow us to measure improvement in hypoglycemia awareness.

NCT ID: NCT03079921 Active, not recruiting - Hypoglycemia Clinical Trials

Adrenergic System in Islet Transplantation

Start date: January 20, 2017
Phase: Early Phase 1
Study type: Interventional

To determine the effect of sympathetic neural and hormonal (epinephrine) input on islet cell hormonal responses to insulin-induced hypoglycemia in type 1 diabetic recipients of intrahepatic islet transplantation. We hypothesize that α-adrenergic (neural) blockage will abolish insulin-mediated suppression of C-peptide, attenuating α-cell glucagon secretion during hypoglycemia, and that β-adrenergic (hormonal) blockage will have no effect. Glucose counterregulatory responses will be measured during hyperinsulinemic euglycemic-hypoglycemic clamps on three occasions with randomized, double-blind administration of the α-adrenergic blocker phentolamine, the β-adrenergic blocker propranolol, or placebo. The demonstration of neural rather than hormonal regulation of the transplanted islet cell response to hypoglycemia is critical for understanding the mechanism for protection from hypoglycemia afforded by intrahepatically transplanted.